Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease

References

• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283. doi:10.1016/j.jtos.2017.05.008
   PubMed Web of Science ®Google Scholar
• Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802–812. doi:10.1016/j.jtos.2017.08.003
   PubMed Web of Science ®Google Scholar
• Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628. doi:10.1016/j.jtos.2017.05.006
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137(2):337–342. doi:10.1016/j.ajo.2003.10.036
   PubMed Web of Science ®Google Scholar
• Tauber J, Schechter BA, Bacharach J, et al. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. Clin Ophthalmol. 2018;12:1921–1929. doi:10.2147/OPTH.S175065
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107(4):631–639. doi:10.1016/S0161-6420(99)00176-1
   PubMed Web of Science ®Google Scholar
• Baudouin C, de la Maza MS, Amrane M, et al. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease. Eur J Ophthalmol. 2017;27(6):678–685. doi:10.5301/ejo.5001002
   PubMed Web of Science ®Google Scholar
• Sun Pharmaceutical Industries, Inc. CEQUA™ (Cyclosporine Ophthalmic Solution 0.09%). Full Prescribing Information. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; 2018.
   Google Scholar
• Allergan. RESTASIS^® (Cyclosporine Ophthalmic Emulsion) 0.05% for Topical Ophthalmic Use. Full prescribing information. Irvine, CA: Allergan; 2017.
   Google Scholar
• Santen SAS. IKERVIS^® (Ciclosporin Ophthalmic Emulsion) 1 Mg/Ml, for Topical Ophthalmic Use. Full prescribing information. Evry, France: Santen SAS; 2015.
   Google Scholar
• Lallemand F, Schmitt M, Bourges JL, Gurny R, Benita S, Garrigue JS. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm. 2017;117:14–28. doi:10.1016/j.ejpb.2017.03.006
   PubMed Web of Science ®Google Scholar
• Vaishya RD, Khurana V, Patel S, Mitra AK. Controlled ocular drug delivery with nanomicelles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6(5):422–437. doi:10.1002/wnan.1272
   PubMed Web of Science ®Google Scholar
• Xiao F, Han M, Wang X, et al. Animal models of Sjogren’s syndrome: an update. Clin Exp Rheumatol. 2019;37(3):209–216.
   Web of Science ®Google Scholar
• Vitali C, Del Papa N. Classification criteria for Sjögren’s syndrome. In: Sjögren’s Syndrome Elsevier. 2016;47–60.
   Google Scholar
• Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510. doi:10.1016/j.jtos.2017.05.011
   PubMed Web of Science ®Google Scholar
• Marko CK, Menon BB, Chen G, Whitsett JA, Clevers H, Gipson IK. Spdef null mice lack conjunctival goblet cells and provide a model of dry eye. Am J Pathol. 2013;183(1):35–48. doi:10.1016/j.ajpath.2013.03.017
   Web of Science ®Google Scholar
• McClellan AJ, Volpe EA, Zhang X, et al. Ocular surface disease and dacryoadenitis in aging C57BL/6 mice. Am J Pathol. 2014;184(3):631–643. doi:10.1016/j.ajpath.2013.11.019
   PubMed Web of Science ®Google Scholar
• Malhotra R, Devries DK, Luchs J, et al. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies. Cornea. 2019;38(10):1259. doi:10.1097/ICO.0000000000001989
   PubMed Web of Science ®Google Scholar
• Sheppard J, Kannarr S, Luchs J, et al. Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study. Eye Contact Lens. 2020;46(1):S14–S19. doi:10.1097/ICL.0000000000000636
   Web of Science ®Google Scholar
• Goldberg DF, Malhotra RP, Schechter BA, et al. 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease. Ophthalmology. 2019;126(9):1230–1237. doi:10.1016/j.ophtha.2019.03.050
   PubMed Web of Science ®Google Scholar
• Stonecipher KG, Torkildsen GL, Ousler GW 3rd, Morris S, Villanueva L, Hollander DA. The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye. Clin Ophthalmol. 2016;10:887–895. doi:10.2147/OPTH.S101627
   PubMed Web of Science ®Google Scholar
• Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled Phase III clinical studies. Br J Ophthalmol. 2019;103(1):125–131. doi:10.1136/bjophthalmol-2017-311801
   PubMed Web of Science ®Google Scholar
• Gipson IK. Goblet cells of the conjunctiva: A review of recent findings. Prog Retin Eye Res. 2016;54:49–63. doi:10.1016/j.preteyeres.2016.04.005
   PubMed Web of Science ®Google Scholar
• Dartt DA, Hodges RR, Serhan CN. Immunoresolvent Resolvin D1 Maintains the Health of the Ocular Surface. Adv Exp Med Biol. 2019;1161:13–25.
   Web of Science ®Google Scholar
• Ko BY, Xiao Y, Barbosa FL, de Paiva CS, Pflugfelder SC. Goblet cell loss abrogates ocular surface immune tolerance. JCI Insight. 2018;3(3). doi:10.1172/jci.insight.98222
   Web of Science ®Google Scholar
• Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120(3):330–337. doi:10.1001/archopht.120.3.330
   PubMedGoogle Scholar
• Ralph R. Conjunctival goblet cell density in normal subjects and in dry eye syndromes. Invest Ophthalmol Vis Sci. 1975;14(4):299–302.
   Google Scholar
• Hamrah P, Alipour F, Jiang S, Sohn JH, Foulks GN. Optimizing evaluation of Lissamine Green parameters for ocular surface staining. Eye. 2011;25(11):1429–1434. doi:10.1038/eye.2011.184
   PubMed Web of Science ®Google Scholar